438 related articles for article (PubMed ID: 2332772)
1. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
Rinehart J; Malspeis L; Young D; Neidhart J
Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects.
Rinehart JJ; Young D; Laforge J; Colborn D; Neidhart JA
Cancer Res; 1987 May; 47(9):2481-5. PubMed ID: 3567933
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy.
Schiller JH; Storer B; Willson JK; Borden EC
Cancer Treat Rep; 1987 Oct; 71(10):945-52. PubMed ID: 3115570
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma.
Buzaid AC; Robertone A; Kisala C; Salmon SE
J Clin Oncol; 1987 Jul; 5(7):1083-9. PubMed ID: 3598612
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of recombinant beta ser 17 interferon in the treatment of cancer.
Sarna G; Pertcheck M; Figlin R; Ardalan B
Cancer Treat Rep; 1986 Dec; 70(12):1365-72. PubMed ID: 3791249
[TBL] [Abstract][Full Text] [Related]
7. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
[TBL] [Abstract][Full Text] [Related]
8. Biological and clinical effects of interferon-beta ser at two doses.
Borden EC; Rinehart JJ; Storer BE; Trump DL; Paulnock DM; Teitelbaum AP
J Interferon Res; 1990 Dec; 10(6):559-70. PubMed ID: 2086672
[TBL] [Abstract][Full Text] [Related]
9. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration.
Muss HB; Costanzi JJ; Leavitt R; Williams RD; Kempf RA; Pollard R; Ozer H; Zekan PJ; Grunberg SM; Mitchell MS
J Clin Oncol; 1987 Feb; 5(2):286-91. PubMed ID: 3543247
[TBL] [Abstract][Full Text] [Related]
10. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma.
Fosså SD; de Garis ST; Heier MS; Flokkmann A; Lien HH; Salveson A; Moe B
Cancer; 1986 Apr; 57(8 Suppl):1700-4. PubMed ID: 3948141
[TBL] [Abstract][Full Text] [Related]
11. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
12. Recombinant interferon beta: a phase I-II trial in children with recurrent brain tumors.
Allen J; Packer R; Bleyer A; Zeltzer P; Prados M; Nirenberg A
J Clin Oncol; 1991 May; 9(5):783-8. PubMed ID: 2016620
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
14. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.
Figlin RA; deKernion JB; Maldazys J; Sarna G
Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656
[TBL] [Abstract][Full Text] [Related]
15. Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma.
Mani S; Todd M; Poo WJ
Am J Clin Oncol; 1996 Apr; 19(2):187-9. PubMed ID: 8610647
[TBL] [Abstract][Full Text] [Related]
16. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
[TBL] [Abstract][Full Text] [Related]
18. Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma.
Mani S; Poo WJ
Am J Clin Oncol; 1996 Apr; 19(2):149-53. PubMed ID: 8610639
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.
Rinehart JJ; Malspeis L; Young D; Neidhart JA
J Biol Response Mod; 1986 Aug; 5(4):300-8. PubMed ID: 3090208
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
Lopez Hänninen E; Kirchner H; Atzpodien J
J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
